AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Vir Biotech Stock Surges on BofA Upgrade to Buy
ByAinvest
Wednesday, Aug 27, 2025 3:41 pm ET1min read
Vir Biotechnology's stock surged 12% after Bank of America upgraded it to Buy from Neutral, citing upside potential in its late-stage liver disease program. The bank raised its price target to $14, implying a 215% upside, and increased its probability of success for the program to 55%. It also highlighted hidden value in Vir's oncology pipeline, with combined unadjusted peak sales potentially exceeding $4 billion.
Vir Biotechnology (NASDAQ:VIR) saw its stock surge 17% on Wednesday following an upgrade by BofA Securities from Neutral to Buy, with a new price target of $14.00. The stock was trading at $4.44 before the upgrade, which suggests substantial upside potential [1].The upgrade comes as BofA Securities believes the market is underestimating the potential of Vir’s treatment for severe liver disease caused by hepatitis delta virus (HDV). Analyst Geoff Meacham projects that this treatment could generate over $1 billion in unadjusted peak sales [2]. Additionally, the analyst noted that minimal value is currently attributed to Vir’s T-cell engager (TCE) oncology programs despite initial proof-of-concept data [2].
Meacham highlighted two key catalysts driving upside over the next 12 months. The first is spending on the pivotal ECLIPSE phase 3 trials, which is justified given derisking data from last year, with potentially share-moving trial readouts expected in late 2026. The second catalyst is the hidden value in Vir’s masked TCEs, which may be differentiated from competitors in terms of dosing frequency and efficacy in major cancer types including breast, prostate, and colorectal cancer [2].
The upgrade also comes as Vir works to expand its pipeline beyond infectious diseases into oncology and hepatology, with investors showing renewed interest in the company’s development programs [1].
References:
[1] https://www.investing.com/news/stock-market-news/vir-biotechnology-stock-soars-after-bofa-upgrade-14-target-93CH-4213052
[2] https://www.investing.com/news/analyst-ratings/bofa-securities-upgrades-vir-biotechnology-stock-to-buy-on-hdv-treatment-potential-93CH-4212478
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet